NEW YORK (GenomeWeb) – Qiagen has launched the third tranche of a share repurchase program for up to approximately $30 million. 

In a document filed with the US Securities and Exchange Commission, the firm said that a maximum of 2 million shares will be repurchased at a maximum per-share price no greater than 10 percent above the average closing price of the last five trading days prior to the day of purchase on the Frankfurt Stock Exchange. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.